Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VSIR | Q9H7M9 | 9/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 8/20 | 0.34 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30153046 | 1.00 | VSIR (0.37) | VSIRCD274PDCD1KCNH2PDCD1LG2 | |
| SCHEMBL30152910 | 0.93 | VSIR (0.37) | VSIRCD274PDCD1KCNH2PDCD1LG2 | |
| SCHEMBL24820311 | 0.93 | VSIR (0.37) | VSIRCD274PDCD1PDCD1LG2MAP3K5 | |
| SCHEMBL24820267 | 0.93 | VSIR (0.37) | VSIRCD274PDCD1KCNH2PDCD1LG2 | |
| SCHEMBL24818723 | 0.92 | VSIR (0.36) | VSIRCD274PDCD1PDCD1LG2MAP3K5 | |
| SCHEMBL30152834 | 0.92 | VSIR (0.36) | VSIRCD274PDCD1PDCD1LG2MAP3K5 | |
| SCHEMBL30152922 | 0.91 | VSIR (0.35) | VSIRCD274PDCD1KCNH2PDCD1LG2 | |
| SCHEMBL24820053 | 0.91 | VSIR (0.35) | VSIRCD274PDCD1KCNH2PDCD1LG2 | |
| SCHEMBL24820153 | 0.91 | VSIR (0.35) | VSIRCD274PDCD1KCNH2PDCD1LG2 | |
| SCHEMBL24818891 | 0.91 | VSIR (0.35) | VSIRCD274PDCD1PDCD1LG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |